Program Description
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype of non-Hodgkin lymphoma, with 30% to 40% of patients continuing to experience relapse or who are refractory to initial standard-of-care chemoimmunotherapy. Though treatment options for patients with relapsed/refractory (R/R) disease have been limited, recently developed therapies, such as chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates, and investigational T-cell engaging bispecific antibodies, have shown to improve outcomes in these patients. This activity will summarize new and emerging data for these therapies in the DLBCL treatment landscape presented at the 2022 American Society of Hematology Annual Meeting. The discussion will also focus on barriers to the optimal uptake of these treatments, namely financial impact and access to care, and strategies for pharmacists to assess cost-effectiveness and value of these therapies in clinical practice.
Target audience: Managed care and oncology pharmacists
Type of activity: Application
Release date: December 21, 2022
Expiration date: March 31, 2024
Time to complete activity: 1 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the rationale for investigation of novel immunotherapeutic mechanisms to meet the clinical needs of patients with diffuse large B-cell lymphoma (DLBCL)
- Apply updated clinical information presented at ASH 2022 to differentiate novel pharmacologic strategies for the treatment of DLBCL
- Construct a comprehensive care plan that accounts for financial and logistical challenges facing patients with DLBCL who are eligible for treatment with novel immunotherapies
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
